文章：

IMPDH1与IMPDH2比值降低使胶质瘤对化疗更敏感

Lower ratio of IMPDH1 to IMPDH2 sensitizes gliomas to chemotherapy 

原文发布日期：2024-06-13 

英文摘要：

Gliomas are the most common primary tumors of the central nervous system, with approximately half of patients presenting with the most aggressive form of glioblastoma. Although several molecular markers for glioma have been identified, they are not sufficient to predict the prognosis due to the extensive genetic heterogeneity within glioma. Our study reveals that the ratio of IMPDH1 to IMPDH2 expression levels serves as a molecular indicator for glioma treatment prognosis. Patients with a higher IMPDH1/IMPDH2 ratio exhibit a worse prognosis, while those with a lower ratio display a more favorable prognosis. We further demonstrate that IMPDH1 plays a crucial role in maintaining cellular GTP/GDP levels following DNA damage compared to IMPDH2. In the absence of IMPDH1, cells experience an imbalance in the GTP/GDP ratio, impairing DNA damage repair capabilities and rendering them more sensitive to TMZ. This study not only introduces a novel prognostic indicator for glioma clinical diagnosis but also offers innovative insights for precise and stratified glioma treatment. 

摘要翻译：

胶质瘤是中枢神经系统中最常见的原发性肿瘤，约半数患者表现为最具侵袭性的胶质母细胞瘤。尽管已鉴定出多个胶质瘤分子标志物，但由于肿瘤内部存在广泛的遗传异质性，这些标志物尚不足以准确预测预后。我们的研究揭示IMPDH1与IMPDH2表达水平的比值可作为胶质瘤治疗预后的分子指标——IMPDH1/IMPDH2比值较高的患者预后较差，而比值较低者则预后更佳。进一步研究发现，在DNA损伤后维持细胞GTP/GDP水平方面，IMPDH1比IMPDH2发挥着更关键的作用。缺乏IMPDH1会导致细胞GTP/GDP比例失衡，削弱DNA损伤修复能力，从而增强其对替莫唑胺（TMZ）的敏感性。本研究不仅为胶质瘤临床诊断提供了新型预后指标，更为实现精准化、分层化的胶质瘤治疗提供了新思路。

原文链接：

Lower ratio of IMPDH1 to IMPDH2 sensitizes gliomas to chemotherapy